Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults

Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Partici...

Full description

Saved in:
Bibliographic Details
Main Authors: Joyce K. Keithley (Author), Barbara Swanson (Author), Susan L. Mikolaitis (Author), Mark DeMeo (Author), Janice M. Zeller (Author), Lou Fogg (Author), Jehan Adamji (Author)
Format: Book
Published: Hindawi Limited, 2013-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8201e02e8dae47e29fdda05cf6d90a2d
042 |a dc 
100 1 0 |a Joyce K. Keithley  |e author 
700 1 0 |a Barbara Swanson  |e author 
700 1 0 |a Susan L. Mikolaitis  |e author 
700 1 0 |a Mark DeMeo  |e author 
700 1 0 |a Janice M. Zeller  |e author 
700 1 0 |a Lou Fogg  |e author 
700 1 0 |a Jehan Adamji  |e author 
245 0 0 |a Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults 
260 |b Hindawi Limited,   |c 2013-01-01T00:00:00Z. 
500 |a 2090-0708 
500 |a 2090-0716 
500 |a 10.1155/2013/610908 
520 |a Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. Results. A total of 53 participants (18-65 years of age; BMI 25-35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (−.40±.06 and −.43±.07, resp.) or other efficacy outcomes or in any of the safety outcomes. Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600. 
546 |a EN 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Journal of Obesity, Vol 2013 (2013) 
787 0 |n http://dx.doi.org/10.1155/2013/610908 
787 0 |n https://doaj.org/toc/2090-0708 
787 0 |n https://doaj.org/toc/2090-0716 
856 4 1 |u https://doaj.org/article/8201e02e8dae47e29fdda05cf6d90a2d  |z Connect to this object online.